Biotinylated Human FGFR4 beta Protein
Catalog No: FGFR4-HB002
- Species
- Human
- Expression System
- HEK293
- Tag
- His, Avi
Product overview
Recombinant Biotinylated Human FGFR4 beta Protein is expressed in HEK293 cells with a His tag and Avi tag at the C-terminus. It contains amino acid residues Pro152-Asp369 (UniProt accession: P22455-1).
Product Details
- Molecular Aliases
- FGFR4 beta; CD334; FGF R4; FGFR4; FGFR-4; JTK2; TKF
- Protein Length
- Pro152-Asp369
- Expression System
- HEK293
- Theoretical Molecular Weight
- The protein has a predicted MW of 26.90 kDa. Due to glycosylation, the protein migrates to 40-60 kDa based on Bis-Tris PAGE result.
- Purity
- > 95% as determined by Bis-Tris PAGE
- Endotoxin
- Less than 1 EU per μg by the LAL method.
- Buffer / Formulation
- Lyophilized from 0.22 μm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.
- State
- Lyophilized
- Storage Conditions
- -20 to -80°C for 12 months as supplied from date of receipt. -80°C for 3 months after reconstitution. Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
- Reconstitution Advice
- Dissolve the lyophilized protein in distilled water. Please refer to the Certificate of Analysis for detailed instructions.
Data Display
Biotinylated Human FGFR4 beta on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.
Background
Fibroblast growth factor receptor 4 (FGF R4), also known as CD334, is a 110 kDa glycosylated transmembrane receptor tyrosine kinase. Tyrosine-protein kinase that acts as cell-surface receptor for fibroblast growth factors and plays a role in the regulation of cell proliferation, differentiation and migration, and in regulation of lipid metabolism, bile acid biosynthesis, glucose uptake, vitamin D metabolism and phosphate homeostasis. Required for normal down-regulation of the expression of CYP7A1, the rate-limiting enzyme in bile acid synthesis, in response to FGF19.
References
- Katoh, Masaru. FGFR inhibitors: Effects on cancer cells, tumor microenvironment and whole-body homeostasis (Review)[J]. International Journal of Molecular Medicine, 2016.
Have questions about this product?
Our technical team can help with product selection, application questions and order support.